{"meta":{"totalResults":3,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Keytruda"},{"type":"Synonym","name":"pembrolizumab biosimilar RPH-075"},{"type":"Synonym","name":"pembrolizumab biosimilar SB27"},{"type":"CodeName","name":"RPH-075"},{"type":"Synonym","name":"anti-PD-1 monoclonal antibody MK-3475"},{"type":"Synonym","name":"immunoglobulin G4, anti-(human programmed cell death 1)"},{"type":"Synonym","name":"humanized mouse monoclonal (228-L-proline(H10-S>P))gamma 4 heavy chain (134-218')-disulfide with humanized mouse monoclonal kappa light chain dimer (226-226'':229-229'')-bisdisulfide"},{"type":"CodeName","name":"MK-3475"},{"type":"CodeName","name":"SCH 900475"},{"type":"ObsoleteName","name":"lambrolizumab"},{"type":"Synonym","name":"pembrolizumab biosimilar MB12"},{"type":"CASRegistryName","name":"1374853-91-4"},{"type":"ChemicalStructureName","name":"immunoglobulin G4, anti-(human programmed cell death 1); humanized mouse monoclonal (228-L-proline(H10-S>P))gamma 4 heavy chain (134-218')-disulfide with humanized mouse monoclonal kappa light chain dimer (226-226'':229-229'')-bisdisulfide"},{"type":"Synonym","name":"pembrolizumab biosimilar BCD-201"},{"type":"Synonym","name":"pembrolizumab biosimilar Q"},{"type":"CodeName","name":"BCD-201"},{"type":"Synonym","name":"pembrolizumab biosimilar QL2107"},{"type":"CodeName","name":"QL2107"}],"definition":{"html":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","text":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab","text":"Pembrolizumab"},"nciConceptId":"C106432","nciConceptName":"Pembrolizumab","termId":695789,"name":"pembrolizumab","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"pembrolizumab"},{"aliases":[{"type":"CodeName","name":"MK-1308A"},{"type":"CodeName","name":"MK1308A"},{"type":"CodeName","name":"MK 1308A"},{"type":"Synonym","name":"pembrolizumab/quavonlimab"},{"type":"Synonym","name":"pembrolizumab-quavonlimab"},{"type":"Synonym","name":"quavonlimab/pembrolizumab MK-1308A"},{"type":"Synonym","name":"antibodies combination formulation MK-1308A"},{"type":"Synonym","name":"pembrolizumab/quavonlimab formulation MK-1308A"}],"definition":{"html":"A combination formulation containing fixed doses of the two monoclonal antibodies pembrolizumab and quavonlimab, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pembrolizumab/quavonlimab MK-1308A, pembrolizumab, a monoclonal antibody directed against the human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1), targets and binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity. Quavonlimab, a monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), targets and binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.\n","text":"A combination formulation containing fixed doses of the two monoclonal antibodies pembrolizumab and quavonlimab, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pembrolizumab/quavonlimab MK-1308A, pembrolizumab, a monoclonal antibody directed against the human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1), targets and binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity. Quavonlimab, a monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), targets and binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C200832","nciConceptName":"Pembrolizumab/Quavonlimab MK-1308A","termId":813212,"name":"pembrolizumab/quavonlimab MK-1308A","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"pembrolizumab-quavonlimab-mk-1308a"},{"aliases":[{"type":"CodeName","name":"MK-3475A"},{"type":"CodeName","name":"MK3475A"},{"type":"CodeName","name":"MK 3475A"},{"type":"Synonym","name":"pembrolizumab-MK-5108 combination MK-3475A"},{"type":"Synonym","name":"hyaluronidase and pembrolizumab"},{"type":"Synonym","name":"pembrolizumab/hyaluronidase"},{"type":"Synonym","name":"hyaluronidase/pembrolizumab"},{"type":"Synonym","name":"MK-5180 and pembrolizumab"},{"type":"Synonym","name":"MK-5180/pembrolizumab"},{"type":"Synonym","name":"pembrolizumab and hyaluronidase"}],"definition":{"html":"A fixed-dose co-formulation composed of pembrolizumab, a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against human cell surface receptor PD-1 (programmed death-1; programmed cell death-1; cluster of differentiation 279; CD279), and MK-5180, a recombinant form of human hyaluronidase, with potential immune checkpoint inhibitory and antineoplastic activities. Upon subcutaneous administration of recombinant human hyaluronidase and pembrolizumab, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of pembrolizumab into the systemic circulation. In turn, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1; cluster of differentiation 274; CD274), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity. When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs.","text":"A fixed-dose co-formulation composed of pembrolizumab, a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against human cell surface receptor PD-1 (programmed death-1; programmed cell death-1; cluster of differentiation 279; CD279), and MK-5180, a recombinant form of human hyaluronidase, with potential immune checkpoint inhibitory and antineoplastic activities. Upon subcutaneous administration of recombinant human hyaluronidase and pembrolizumab, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of pembrolizumab into the systemic circulation. In turn, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1; cluster of differentiation 274; CD274), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity. When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs."},"drugInfoSummaryLink":null,"nciConceptId":"C200181","nciConceptName":"Recombinant Human Hyaluronidase and Pembrolizumab","termId":806777,"name":"recombinant human hyaluronidase and pembrolizumab","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"recombinant-human-hyaluronidase-and-pembrolizumab"}],"links":null}